Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 26, 2011

Biogen Idec Reports Positive Data from Second Phase III Trial with Multiple Sclerosis Drug

  • Biogen Idec reported positive topline data from a second Phase III study with its oral drug candidate BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis (RRMS). Results from the Confirm study follow less than a week after Biogen Idec reported positive results from the first Phase III BG-12 study, Define.

    The Confirm trial showed that treating RRMS patients using either twice- or thrice-daily oral BG-12 reduced the annualized relapse rate (ARR) by 44% and 51%, respectively, compared with placebo. Treatment with the comparator reference drug, subcutaneous glatiramer acetate, resulted in a 29% reduction in ARR at two years.

    BG-12 therapy in addition met all secondary relapse and MRI endpoints. “We now have strong positive results for BG-12 in two robust pivotal clinical trials with more than 2,600 patients,” remarks Doug Williams, Ph.D., Biogen Idec executive vp for R&D. “We are gratified by these strong efficacy and safety results, which, when combined with BG-12’s oral route of administration, position it as a potentially important MS therapy.” 

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »